|本期目录/Table of Contents|

[1]夏伦云,樊亚童,李政稷,等.CD24在非酒精性脂肪性肝病中的表达及与疾病进展的相关性研究[J].天津医科大学学报,2025,31(05):469-472,481.[doi:10.20135/j.issn.1006-8147.2025.05.0469]
　XIA Lunyun,FAN Yatong,LI Zhengji,et al.The expression of CD24 in nonalcoholic fatty liver disease and its correlation with disease progression[J].Journal of Tianjin Medical University,2025,31(05):469-472,481.[doi:10.20135/j.issn.1006-8147.2025.05.0469]
点击复制

CD24在非酒精性脂肪性肝病中的表达及与疾病进展的相关性研究(PDF)
分享到：

《天津医科大学学报》[ISSN:1006-8147/CN:12-1259/R]

卷:
31卷
期数:
2025年05期
页码:
469-472,481
栏目:
临床医学
出版日期:
2025-09-20

文章信息/Info

Title:
The expression of CD24 in nonalcoholic fatty liver disease and its correlation with disease progression
文章编号:
1006-8147(2025)05-0469-05
作者:
夏伦云1; 2; 樊亚童3; 李政稷2; 黄芳2; 孟超2; 张学军1
1.天津医科大学基础医学院免疫学系，天津市细胞和分子免疫重点实验室，天津医科大学免疫微环境与疾病省部共建教育部重点实验室，天津 300070；2.天津市第二人民医院检验科，天津 300192；3.天津医科大学肿瘤医院输血科，天津 300060
Author(s):
XIA Lunyun1; 2;  FAN Yatong3;  LI Zhengji2;  HUANG Fang2;  MENG Chao2;  ZHANG Xuejun1
1.Department of Immunology， School of Basic Medicine， Tianjin Medical University， Tianjin Key Laboratory of Cellular and Molecular Immunity， Key Laboratory of Immunological Microenvironment and Disease， Tianjin Medical University， Tianjin 300070， China； 2.Department of Laboratory， Tianjin Second People′s Hospital， Tianjin 300192， China； 3.Department of Blood Transfusion， Tianjin Medical University Cancer Institute and Hospital， Tianjin 300060， China
关键词:
CD24; 巨噬细胞; 非酒精性单纯性脂肪肝; 非酒精性脂肪性肝炎
Keywords:
CD24;  macrophage;  nonalcoholic simple fatty liver;  nonalcoholic steatohepatitis
分类号:
R575
DOI:
10.20135/j.issn.1006-8147.2025.05.0469
文献标志码:
A
摘要:
目的：研究非酒精性脂肪性肝病（NAFLD）患者肝组织中CD24表达及其与疾病进展的关系。方法：回顾性分析2021年1月至2023年12月天津市第二人民医院收治的21例非酒精性单纯性脂肪肝（NAFL）和49例非酒精性脂肪性肝炎（NASH）患者肝组织切片及临床资料。根据活动度积分（NAS）分为NAFL组和NASH组，比较两组间临床资料，并进一步探讨CD24表达与NASH患者临床特征的关系。通过流式细胞术检测NAFL组（n=10）和NASH组（n=20）外周血中CD24表达情况。结果：NASH组肝损伤和纤维化指标显著高于NAFL组（P<0.05）。与NAFL组相比，NASH组肝组织中CD24表达显著升高（P<0.000 1）。肝组织中CD24表达与AST、CAP、LSM和NAS评分呈正相关（r=0.313、0.308、0.579、0.415，均P<0.05）。流式结果显示NASH组外周血中CD24的平均荧光强度（MFI）显著高于NAFL组（t=3.675，P<0.001）。结论：CD24表达与NAFLD炎症和疾病严重程度显著正相关。
Abstract:
Objective： To study the expression of CD24 in liver tissue of patients with nonalcoholic fatty liver disease （NAFLD） and its relationship with disease progression. Methods： A retrospective analysis was conducted on liver tissue sections and clinical data of 21 patients with nonalcoholic simple fatty liver （NAFL） and 49 patients with nonalcoholic steatohepatitis （NASH） admitted to the Second People′s Hospital of Tianjin from January 2021 to December 2023. The patients were divided into NAFL and NASH groups based on the activity score （NAS）. Clinical data between the two groups were compared， and further exploration was made regarding the relationship between CD24 expression and clinical characteristics of NASH patients. The expression of CD24 in peripheral blood of NAFL group （n=10） and NASH group （n=20） was detected by flow cytometry. Results： The liver injury and fibrosis indicators were significantly higher in NASH group than those in NAFL group （P<0.05）. In comparison to the NAFL group， the expression of CD24 in liver tissue was significantly elevated in the NASH group （P<0.000 1）. The expression of CD24 in liver tissue showed a positive correlation with AST， CAP， LSM， and NAS scores（r=0.313， 0.308， 0.579，0.415， all P<0.05）. Flow cytometry results indicated that the mean fluorescence intensity （MFI） of CD24 in peripheral blood was significantly higher in NASH group than that in the NAFL group（t=3.675， P<0.001）. Conclusion：The expression of CD24 is significantly positively correlated with inflammation and disease severity in NAFLD.

参考文献/References:

[1] YOUNOSSI Z M， GOLABI P， PAIK J M， et al. The global epidemiology of nonalcoholic fatty liver disease （NAFLD） and nonalcoholic steatohepatitis （NASH）： a systematic review [J]. Hepatology， 2023， 77（4）： 1335-1347.
[2] YOUNOSSI Z M， KOENIG A B， ABDELATIF D， et al. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence， incidence， and outcomes[J]. Hepatology， 2016， 64（1）： 73-84.
[3] FANG X， ZHENG P， TANG J， et al. CD24： from A to Z[J]. Cell Mol Immunol， 2010， 7（2）： 100-103.
[4] ARENDT B M， COMELLI E M， MA D W， et al. Altered hepatic gene expression in nonalcoholic fatty liver disease is associated with lower hepatic n-3 and n-6 polyunsaturated fatty acids[J]. Hepatology， 2015， 61（5）： 1565-1578.
[5] AMIN M A， RAGAB H M， MAKSOUD N A， et al. CD24 gene expression as a risk factor for non-alcoholic fatty liver disease[J]. Diagnostics （Basel）， 2023， 13（5）： 984.
[6] 中华医学会肝病学分会. 代谢相关（非酒精性）脂肪性肝病防治指南（2024年版） [J]. 中华肝脏病杂志， 2024， 32（5）： 418-434.
[7] XU N， XII Q， LI J， et al. Improvement in liver stiffness measurement for diagnosis of liver fibrosis in patients with concurrent chronic hepatitis B and nonalcoholic fatty liver disease[J]. J Int Med Res， 2020， 48（2）： 1-12.
[8] GOH GBB， ISSA D， LOPEZ R， et al. The development of a non-invasive model to predict the presence of non-alcoholic steatohepatitis in patients with non-alcoholic fatty liver disease[J]. J Gastr-oenterol Hepatol， 2016， 31（5）： 995-1000.
[9] HUANG S， SUN C， HOU Y， et al. A comprehensive bioinformatics analysis on multiple gene expression omnibus datasets of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis[J]. Sci Rep， 2018， 8（1）： 7630.
[10] FENG J， WEI T， CUI X， et al. Identification of key genes and pathways in mild and severe nonalcoholic fatty liver disease by integrative analysis[J]. Chronic Dis Transl Med， 2021， 7（4）： 276-286.
[11] VERMA S， JENSEN D， HART J， et al. Predictive value of ALT levels for non-alcoholic steatohepatitis （NASH） and advanced fibr-osis in non-alcoholic fatty liver disease （NAFLD） [J]. Liver Int， 2013， 33（9）： 1398-1405.
[12] ANA P G，ESTHER Q G，PABLO J， et al. Non-invasive evaluation of steatosis and fibrosis in the liver in adults patients living with cystic fibrosis[J]. J Cyst Fibrosis， 2025， 24（3）： 581-589.
[13] Xi W F，YANG A M. Association between cardiometabolic index and controlled attenuation parameter in U.S. adults with NAFLD： findings from NHANES （2017-2020）[J]. Lipids Health Dis，2024，23（1）：40.
[14] EDDOWES P J， SASSO M， ALLISON M，etal. Accuracy of fibroscan controlled attenuation parameter and liver stiffness measurement in assessing steatosis and fibrosis in patients with nonalcoholic fatty liver disease[J]. Gastroenterology， 2019， 156（6）： 1717-1730.
[15] AMARILYS S R， DAGMARY P， KATHIA R D， et al. A comparison of brunt′s criteria， the non-alcoholic fatty liver disease activity score （NAS）， and a proposed NAS scoring that includes fibrosis in non-alcoholic fatty liver disease staging[J]. Puerto Rico Health Sci J，2015，34（4）：189-194.

相似文献/References:

[1]樊亚童,郑鉴,肖俊,等.炎症反应中巨噬细胞的Siglec-G分子对DAMPs和PAMPs的识别及调节作用[J].天津医科大学学报,2018,24(02):93.
　FAN Ya-tong,ZHENG Jian,XIAO Jun,et al.Identification of DAMPs and PAMPs by Siglec-G in macrophages and its regulatory effect on DAMPs and PAMPs in inflammatory response[J].Journal of Tianjin Medical University,2018,24(05):93.
[2]刘颂平综述,华克勤审校.巨噬细胞在子宫内膜异位症发生发展中的作用研究现状[J].天津医科大学学报,2018,24(03):271.

备注/Memo

备注/Memo:
基金项目:国家自然科学基金项目（31370891）；天津市卫生健康委员会中医中西医结合科研课题重点项目（2021022）
作者简介:夏伦云（1991-），男，主管技师，硕士在读，研究方向：免疫学；通信作者：张学军，E-mail：xjzh@tmu.edu.cn。
更新日期/Last Update: 2025-10-01